• Equity Capital Markets
  • Debt Capital Markets
  • Private Capital Advisory
  • Mergers & Acquisitions


  • Healthcare


Daniel Lewis, PhD is a Vice President in the Healthcare & Life Sciences group at B. Riley Securities, responsible for advising companies on public and private financings, mergers & acquisitions, and other strategic mandates. He has 16 years of experience in the biopharma sector, working with public and private biotech and medical device companies, across development and commercial stage.

Prior to B. Riley, he was a consultant at Cello Health BioConsulting (now, Lumanity) on over 50 engagements covering scientific, clinical, and commercial strategy for biotech and pharma clients.

Dr. Lewis completed his postdoctoral fellowship in Translational Medicine at Columbia University Medical Center after receiving his PhD and MS in Chemical & Biochemical Engineering from Rutgers University. He received his BS in Chemical Engineering from Columbia University.

B. Riley Securities provides a full suite of investment banking, corporate finance, advisory, research, and sales and trading services. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. B. Riley is nationally recognized and highly ranked for its proprietary small-cap equity research. B. Riley Securities formerly operated as B. Riley FBR following the merger of B. Riley & Co. and FBR & Co.